{
    "nctId": "NCT02062255",
    "briefTitle": "Impact of COX2 on Sera Biomarkers From Obese Subjects",
    "officialTitle": "A Phase 0, Investigator Initiated Study, Evaluating the Impact of COX2 Inhibition on Human Sera Biomarkers From Obese Subjects",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer Survivors",
    "studyType": "INTERVENTIONAL",
    "phase": "EARLY_PHASE1",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "BASIC_SCIENCE",
    "enrollmentCount": 126,
    "primaryOutcomeMeasure": "Biomarker levels",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* At least 18 years of age\n* Post-menopausal as confirmed by medical history\n* Ability to understand the purposes and risks of the study and has signed a written informed consent form approved by the investigator's IRB/Ethics Committee\n\nExclusion Criteria:\n\n* Evidence of active cancer (patients with a prior history of malignancy are encouraged to participate, but due to cytokine levels associated with malignancy there must be no evidence of disease)\n* Cachexia\n* Active systemic illness (infection including viral illnesses such as Hepatitis and HIV)\n* Chronic use of aspirin of omega-3 free fatty acid supplementation within the last 60 days (defined as greater than or equal to 7 consecutive days)\n* Known hypersensitivity to aspirin and/or omega-3 fatty acids\n* Actively receiving a physician-directed regimen of aspirin and/or receiving herapeutic/prophylactic anticoagulation\n* Any aspirin or omega-3 free fatty acid supplementation within the last 14 days\n* Subjects who are pregnant\n* History of medical noncompliance",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}